Plenary Session

VP discusses the LaceWing study in Blood. A Phase 3 RCT of GILT AZA vs AZA; Medical writers; confounding; table 1; balance; and so much more

Timothee Olivier joins me to discuss recent papers: IMPOWER10 Checkmate 816 Path CR/ EFS/ Surrogates Drug Dosing, cGCSF rules and more Bread and butter oncology

The POLO trial, which we first broke on PS Season 1- is back with null OS results. But the trial authors enter the spin cycle. VP goes line by line.

VP explains H index, total cites, papers, US News and World Report rankings and how evaluates researchers and doctors.

VP addresses what to do you if you get an idea from listening to the show, and deconstructs ECHELON-1. Instead of listening we highly recommend you watch the video on YouTube with graphics. This is worth the watch.

How to think about when and how to do RCTs? What are the limitations to observational studies? Smoking. Parachutes. Dostarlimab. Guarantee Time Bias. Confounding. Multiple Hypothesis testing and more

I make the case why this podcast should be your go to for Med, Onc & Policy. I describe my philosophy of Evidence, Empiricism, and show how this connects to many oncology studies. I answer a bunch of Listener Questions

How to read randomized trials in cancer medicine. Phase 2 vs 3, control arm, crossover, post protocol, censoring (the basics), and how law professors and medical professors are different and why it matters.

Lies and Exaggerations about Kids Vaccine I give examples, and show why they are lies

What happens when you treat people with $168,000 a year medicine when most of them will never need treatment, and all of them don't need treatment now

I take a deep dive into the data for the mRNA vaccines for kids under 5 years olds

I sit down with H Jack West. City of Hope. Thoracic Oncology and we have a long discussion about trials; staging; PDL1 thresholds; Driver mutations and post protocol care; ADAURA; Adjuvant; & More

I discuss the timeline of Ratify and Quantum. Was this an ethical trial? Is it sufficient to say a trial is ethical because 50% of participants get something?

The drug has a high response rate and lots of infections, is it active? Yes; Efficacious? ???? I review ASCO2022 updates

Are the results from Luis Diaz as good as touted. What trial should they do going forward? A 100% CR rate in Stage II and III rectal cancer??

My take on the standing ovation for DESTINY Breast 04 Traztuzumab Deruxtecan vs. Investigator choice after endocrine therapy and 1 or 2 chemotherapies for HER2 low

I break down Richardson, et al. NEJM DETERMINATION Transplanters are determined to keep going, should they be? Watch the videos b/c I have lots of great visuals My ASCO Coverage continues

The second paper from #ASCO2022 #ASCO22 that I break down This is one of the most technical papers I breakdown on the channel CT DNA used to omit chemo in Stage II colon cancer Read the book Malignant if you learn from this Watch the YouTube Figures https://youtu.be/QxOBIi7I2BU

Continuous vs. Fixed, 3 vs 2, PFS is the primary endpoint No OS Bad crossover Lots to discuss here I will be covering all the major ASCO papers on @PlenarySession Subscribe to my substack https://vinayprasadmdmph.substack.com/

I am joined by Dr. Katie Sharff, infectious disease doc, to discuss two of her papers on myocarditis after COVID-19 vaccination. https://doi.org/10.1016/j.amjcard.2022.02.039 https://doi.org/10.1101/2021.12.21.21268209

I get back to my roots; I explain surrogate validation and a new JCO paper from the FDA authors on EFS and OS in AML. You won't want to miss it

In this episode I dissect a test negative case control trial; I talk about a famous pancreas cancer study and I revisit the failure of Myeloma trialists

I am joined by Manni Mohyuddin to talk about How I treat frontline transplant eligible myeloma. Vinay Prasad makes the case the entire field of myeloma is corrupt and broken.

I join Dr. Bienen in person to discuss COVID19 and failures in public health

ID ethicist, and brilliant COVID19 commenter